Cargando…
Emerging treatments for postmenopausal osteoporosis – focus on denosumab
The pathway of the receptor activator of the nuclear factor κB ligand (RANKL), RANK and osteoprotegerin (OPG) plays a central role in coupling bone formation and resorption during normal bone turnover and in a wide spectrum of diseases characterized by disturbed bone remodeling, increased bone resor...
Autor principal: | Geusens, Piet |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697589/ https://www.ncbi.nlm.nih.gov/pubmed/19554095 |
Ejemplares similares
-
Progress in osteoporosis and fracture prevention: focus on postmenopausal women
por: Saag, Kenneth G, et al.
Publicado: (2009) -
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011) -
New insights into treatment of osteoporosis in postmenopausal women
por: Geusens, Piet
Publicado: (2015) -
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015) -
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)